Drug Pricing Percocet
View Price per Unit, Price History
Current Pricing Information
The most recent wholesale price for a package of 100 TABLET in 1 BOTTLE is $36.02588 per billable unit.Percocet is a a human prescription drug labeled by Endo Pharmaceuticals Inc. and is priced per "EA" unit. The pricing information is based on the National Average Drug Acquisition Cost (NADAC) and is effective since 01-01-2024.
NADAC pricing data is based on random monthly surveys and reflects the average drug invoice price paid by retail community pharmacies to wholesalers. The data source for this pricing survey was a C/I - Chain or Independent Pharmacy.
The Centers for Medicare and Medicaid Services (CMS) compile the NADAC data based on random monthly surveys on more than 60,000 pharmacies from all 50 states and the District of Columbia. NADAC pricing information is NOT the price paid by end-customers but instead the price paid by pharmacies to drug wholesalers and distributors.
Pricing History
The NADAC wholesale price of Percocet 63481-629-70 has fluctuated from a low of $7.17874 to a high of $36.02588 per billable unit over a period of 10 years and 2 months. The historical price table below includes all the price changes based on the monthly surveys of retail and chain pharmacies taken by the Centers for Medicare and Medicaid Services (CMS).
Effective Date | Price per Unit | Pricing Unit | Pharmacy Type Indicator | Explanation Code | Classification Rate Setting |
---|---|---|---|---|---|
01-01-2024 | $36.02588 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
10-18-2023 | $32.78060 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-01-2023 | $32.82822 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-01-2022 | $29.87100 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
10-20-2021 | $27.18016 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-01-2021 | $27.07997 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
07-22-2020 | $24.64055 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-06-2020 | $24.73354 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
10-23-2019 | $22.50549 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-04-2019 | $22.53075 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
10-17-2018 | $19.59195 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-05-2018 | $19.62579 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
08-23-2017 | $17.06590 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
07-01-2017 | $17.04156 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
05-17-2017 | $16.24552 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
04-03-2017 | $16.38583 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
07-01-2016 | $15.60555 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
03-23-2016 | $14.86243 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-05-2016 | $14.90845 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
10-21-2015 | $11.92676 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
01-06-2015 | $11.94394 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
12-17-2014 | $9.55515 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
11-19-2014 | $9.52731 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
03-01-2014 | $9.33244 | EA | C/I - Chain or Independent Pharmacy | Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
11-21-2013 | $7.17874 | EA | C/I - Chain or Independent Pharmacy | Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey. Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation. | B-ANDA - Abbreviated New Drug Application |
The pricing data in this page is based on the National Average Drug Acquisition Cost (NADAC). The NADAC data is compiled by CMS and updated every week. The NADAC dataset is designed to help create a national benchmark reflective of the wholesale prices paid by retails pharmacies to acquire prescription and over-the-counter drugs. The pricing information in this page reflects the reference point that healthcare programs like Medicaid may use to reimburse pharmacies. The pricing data is this page is NOT the price paid by end-customers.
NADAC Pricing Data Last Updated on: April 10, 2024